Renin-angiotensin system blockers and modulation of radiation-induced brain injury

Current Drug Targets

Volumn 11, Issue 11, 2010, Pages 1413-1422

  Robbins, M E ^a   Zhao, W ^a   Garcia Espinosa, M A ^a   Diz, D I ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin peptides; Angiotensin converting enzyme inhibitors; Brain irradiation; Cognitive impairment; Inflammation; Oxidative stress; Renin angiotensin system

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; RAMIPRIL; RAMIPRILAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; BRAIN INJURY; BRAIN METASTASIS; BRAIN RADIATION; BRAIN TUMOR; COGNITIVE DEFECT; HYPERTENSION; KIDNEY; LUNG; MORBIDITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; QUALITY OF LIFE; RADIATION INJURY; ANIMAL; BRAIN; DRUG EFFECT; HUMAN; RADIATION EXPOSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRAIN; BRAIN INJURIES; BRAIN NEOPLASMS; HUMANS; RADIATION INJURIES; RENIN-ANGIOTENSIN SYSTEM;

EID: 79954426550     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111009011413     Document Type: Article

References (126)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. Ca Cancer J Clin 2009; 59: 225-49.
2. Perez C, Brady LW. Principles and practice of radiation oncology. Philadelphia, Lippincott-Raven, 2003.
3. Coleman CN, Stone HB, Moulder JE, et al. Modulation of radiation injury. Science 2004; 304: 693-4.
4. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006; 6: 702-13.
5. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des 2007; 13: 1317-25.
6. Rubin P, Finkelstein J, Shapiro D. Molecular biology mechanisms in the radiation induction of pulmonary injury syndromes: interrelationship between the alveolar macrophages and the septal fibroblast. Int J Radiat Oncol Biol Phys 1992; 24: 93-101.
7. Denham JW, Hauer-Jensen M. The radiotherapeutic injury-a complex "wound". Radiother Oncol 2002; 63: 129-45.
8. Hauer-Jensen M, Wang J, Boerma M, et al. Radiation damage to the gastrointestinal tract: mechanisms, diagnosis, and management. Curr Opin Support Palliat Care 2007; 1: 23-9.
9. Moulder JE, Cohen EP. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 2007; 17: 141-148.
10. Tofilon PJ, Fike JR. The radioresponse of the central nervous system: a dynamic process. Radiat Res 2000; 153: 357-70.
11. Schultheiss TE, Stephens LC. Permanent radiation myelopathy. Br J Radiol 1992; 65: 737-53.
12. Sheline GE, Wara WM, Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980; 6: 1215-8.
13. Crossen JR, Garwood D, Glatstein E, et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiationinduced encephalopathy. J Clin Oncol 1994; 12: 627-42.
14. Johannesen TB, Lien HH, Hole KH, et al. Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy. Radiother Oncol 2003; 69: 169-76.
15. Giovagnoli AR, Boiardi A. Cognitive impairment and quality of life in long-term survivors of malignant brain tumors. Ital J Neurol Sci 1994; 15: 481-8.
16. Meyers CA, Brown PD. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 2006; 24: 1305-9.
17. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006; 355: 1572-82.
18. Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumors in childhood. Lancet Oncol 2004; 5: 399-408.
19. Nathan PC, Patel SK, Dilley K, et al. Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in survivors of childhood cancer. Arch Pediatr Adolesc Med 2007; 161: 798-806.
20. Butler RW, Haser JK. Neurocognitive effects of treatment for childhood cancer. MRDD Research Reviews 2006; 12: 184-91.
21. Li J, Bentzen SM, Li J, et al. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 2008; 71: 64-70.
22. Brown PD, Asher AL, Farace E. Adjuvant whole brain radiotherapy: strong emotions decide but rational studies are needed. Int J Radiat Oncol Biol Phys 2008; 70, 1305-9.
23. Khuntia D, Brown P, Li J, et al. Whole brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24: 1295-304.
24. Shaw EG, Robbins ME. The management of radiation-induced brain injury. Cancer Treat Res 2006; 128: 7-22.
25. Monje M. Cranial radiation therapy and damage to hippocampal neurogenesis. Dev Disabil Rev Res 2008; 14: 238-42.
26. Fike JR, Rosi S, Limoli CL. Neural precursor cells and central nervous system radiation sensitivity. Semin Radiat Oncol 2009; 19: 122-32.
27. Eriksson PS, Perfilieva E, Björk-Erikkson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998; 4: 1313-7.
28. Taupin P, Gage FH. Adult neurogenesis and neural stem cells of the central nervous system in mammals. J Neurosc Res 2002; 6: 745-9.
29. Song H, Stevens CF, Gage FH. Astroglia induce neurogenesis from adult neural stem cells. Nature 2002; 417: 39-44.
30. Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 2000; 425: 479-94.
31. Mizumatsu S, Monje ML, Morhardt DR, et al. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res 2003; 63: 4021-7.
32. Monje ML, Mizumatsu S, Fike JR, et al. Irradiation induced neural precursor-cell dysfunction. Nature Med 2002; 8: 955-61.
33. Raber J, Rola R, LeFevour A, et al. Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res 2004; 162: 39-47.
34. Rola R, Raber J, Rizk A, et al. Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol 2004; 188: 316-30.
35. Monje ML, Vogel H, Masek M, et al. Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 2007; 62: 515-20.
36. Brown WR, Thore CR, Moody DM, et al. Vascular damage after fractionated whole-brain irradiation in rats. Radiat Res 2005; 164: 662-8.
37. Atwood T, Payne VS, Zhao W, et al. Quantitative magnetic resonance spectroscopy reveals a potential relationship between radiation-induced changes in rat brain metabolites and cognitive impairment. Radiat Res 2007; 168: 574-81.
38. Shi L, Adams MM, Long A, et al. Spatial learning and memory deficits following whole-brain irradiation are associated with changes in NMDA receptor subunits in the hippocampus. Radiat Res 2006; 166: 892-9.
39. Villasana L, Acevado S, Poage C, et al. Sex and APOE isoformdependent effects of radiation on cognitive function. Radiat Res 2006; 166: 883-91.
40. Noel F, Gumin GJ, Raju U, et al. Increased expression of prohormone convertase-2 in the irradiated rat brain. FASEB J 1998; 12: 1725-30.
41. Fike JR, Rola R, Limoli CL. Radiation response of neural precursor cells. Neurosurg Clin N Am 2007; 18: 115-27.
42. Zhao W, Diz DI, Robbins ME. Oxidative damage pathways in relation to normal tissue injury. Br J Radiol 2007; 80[Spec No 1]: S23-31.
43. Robbins MEC, Zhao W. Chronic oxidative stress and radiationinduced late normal tissue injury: a review. Int J Radiat Biol 2004; 80: 251-9.
44. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen species and nitrogen species. Brain Pathol 1999; 9: 69-92.
45. Connor JR, Menzies SL. Cellular management of iron in the brain. J Neurol Sci 1995; 134: 33-44.
46. Bast A, Haenen GRMM, Doelman CJA. Oxidants and antioxidants: State of the art. Am J Med 1991; 91: 2S-13S.
47. Peuchen S, Bolanos JP, Heales SJR, et al. Interrelationships between astrocyte function, oxidative stress and antioxidant status within the central nervous system. Prog Neurobiol 1997; 52: 261-81.
48. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 2005; 75: 207-46.
49. Wong CH, Crack PJ. Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemiareperfusion injury. Curr Med Chem 2008; 15: 1-14.
50. Fukuda H, Fukuda A, Zhu C, et al. Irradiation-induced progenitor cell death in the developing brain is resistant to erythropoietin treatment and caspase inhibition. Cell Death Differ 2004; 11: 1166-78.
51. Limoli CL, Rola R, Giedzinski E, et al. Cell-density-dependent regulation of neural precursor cells function. PNAS 2004; 101: 16052-7.
52. Rola R, Sarkissian V, Obenaus A, et al. High-LET radiation induces inflammation and persistent changes in markers of hippocampal neurogenesis. Radiat Res 2005; 164: 556-60.
53. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-15.
54. Banisadr G, Queraud-Lesaux F, Boutterin MC, et al. Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain. J Neurochem 2002; 81: 257-69.
55. Schindler MK, Forbes ME, Robbins ME, et al. Aging-dependent changes in the radiation response of the adult rat brain. Int J Radiat Oncol Biol Phys 2008; 70: 826-34.
56. Diz D. Approaches to establishing angiotensin II as a neurotransmitter revisited. Hypertension 2006; 47: 334-6.
57. Brosnihan KB, Diz DI, Schiavone MT, et al. In: Buckley JP, Ferrario CM Eds, Brain Peptides and Catecholamines in Cardiovascular Regulation. New York, Raven Press, 1987; 313-28.
58. Schinke M, Baltatu O, Bohm M, et al. Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. PNAS 1999; 96: 3975-80.
59. Diz DI. Approaches to establishing angiotensin II as a neurotransmitter revisited. Hypertension 2006; 47: 334-6.
60. Dzau VJ, Ingelfinger J, Pratt RE, et al. Identification of renin and angiotensinogen messenger RNA sequences in mouse and rat brains. Hypertension 1986; 8: 544-8.
61. Lavoie JL, Cassell MD, Gross KW, et al. Localization of renin expressing cells in the brain, by use of a REN-eGFP transgenic model. Physiol Genom 2004; 16: 240-6.
62. Lavoie JL, Cassell MD, Gross KW, et al. Adjacent expression of renin and angiotensinogen in the rostral ventrolateral medulla using a dual-reporter transgenic model. Hypertension 2004; 43: 1116-9.
63. Krob HA, Vinsant SL, Ferrario CM, et al. Angiotensin-(1-7) immunoreactivity in the hypothalamus of the (mRen-2d)27 transgenic rat. Brain Res 1998; 798: 36-45.
64. Nagata S, Kato J, Sasaki K, et al. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 2006; 350: 1026-31.
65. Chappell MC, Westwood BM, Pendergrass KD, et al. Distinct processing pathways for the novel peptides angiotensin-(1-12) in the serum and kidney of the hypertensive mRen2. Lewis rat. Hypertension 2007; 50: E139.
66. Isa K, Garcia-Espinosa MA, Arnold AC, et al. Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2009; 297: R111-5.
67. Isa K, Garcia-Espinosa MA, Shaltout HA, et al. Intracerebroventricular anti-Ang-(1-12)-IgG improves baroreflex sensitivity and heart rate variability in transgenic (mRen2)27 hypertensive rats. FASEB J 2009; 2: 612.3.
68. Elased KM, Cunha TS, Marcondes FK, et al. Brain angiotensinconverting enzymes: role of angiotensin-converting enzyme 2 in processing angiotensin II in mice. Exptl Physiol 2008; 93: 665-75.
69. Diz DI, Garcia-Espinosa MA, Gegick S, et al. Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii redcue baroreceptor reflex sensitivity for heart rate control in rats. Exptl Physiol 2008; 93: 694-700.
70. Diz DI, Kasper SO, Sakima A, et al. Aging and the brain reninangiotensin system: Insights from studies in transgenic rats. Cleveland Clinic J Med 2007; 74(Suppl 1): S95-8.
71. Carter CS, Cesari M, Ambrosius WT, et al. Angiotensinconverting enzyme inhibition, body composition, and physical performance in aged rats. J Gerontol A Biol Sci Med Sci 2004; 59: 416-23.
72. 1 receptor blockade improves metabolic function and provides renoprotection in Fischer 344 rats. Am J Physiol Heart Circ Physiol 2007; 293: H1327-33.
73. Gilliam-Davis S, Gallagher PE, Payne V, et al. Long-term systemic renin-angiotensin system blockade alters expression of renin-angiotensin system components in dorsomedial medulla of Fischer 344 rats. Hypertension 2008; 52: E61.
74. Phillips MI. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension 1997; 29(part 2): 177-87.
75. Paton J, Wang S, Polson J, et al. Signalling across the blood brain barrier by angiotensin II: novel implications for neurogenic hypertension. J Mol Med 2008; 86: 705-10.
76. Naveri L, Stromberg C, Saavedra JM. Angiotensin IV reverses the acute cerebral blood flow reduction after experimental subarachnoid hemorrhage in the rat. J Cereb Blood Flow Metab 1994; 14: 1096-9.
77. 1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004; 35: 1726-31.
78. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25: 485-512.
79. Belcheva I, Ternianov A, Georgiev V. Lateralized learning and memory effects of angiotensin II microinjected into the rat CA1 hippocampal area. Peptides 2000; 21(3): 407-11.
80. Young D, O'Neill K, Jessel T, et al. Characterization of the rat mas oncogene and its high-level expression in the hippocampus and cerebral cortex of rat brain. PNAS 1988; 85: 5339-42.
81. Jung KH, Chu K, Lee ST, et al. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hremorrhage. J Pharmacol Exp Ther 2007; 322: 1051-8.
82. Makino I, Shibata K, Ohgami Y, et al. Transient upregulation of the AT2 receptor mRNA level after global ischemia in the rat brain. Neuropeptides 1996; 30: 596-601.
83. Kusaka I, Kusaka G, Zhou C, et al. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. Am J Physiol Heart Circ Physiol 2004; 286: H2442-51.
84. Thone-Reineke C, Zimmerman M, Neumann C, et al. Are angiotensin receptor blockers neuroprotective? Curr Hypertens Rep 2004; 6: 257-66.
85. Logan E, Diz DI, Ferrario CM, et al. Inhibition of P13 kinase pathway in the nTS of hypertensive rats improves baroreceptor reflex sensitivity. Hypertension 2008; 52: E80[p122].
86. Seyedabadi M, Goodchild AK, Pilowsky PM. Differential role of kinases in brain stem of hypertensive and normotensive rats. Hypertension 2001; 38(5): 1087-92.
87. Carvalheira JB, Torsoni MA, Ueno M, et al. Cross-talk between the insulin and leptin signaling systems in rat hypothalamus 1. Obes Res 2005; 13: 48-57.
88. Camps M, Nicols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000; 14: 6-16.
89. Farooq A, Zhou MM. Structure and regulation of MAPK phosphatases. Cell Signal 2004; 16: 769-79.
90. Guthridge MA, Lopez AF. Phosphotyrosine/phosphoserine binary switches: a new paradigm for the regulation of PI3K signalling and growth factor pleiotropy? Biochem Soc Trans 2007; 35: 250-2.
91. Teng CH, Huang WN, Meng TC. Several dual specificity phosphatases coordinate to control the magnitude and duration of JNK activation in signaling response to oxidative stress. Curr Hypertens Rep 2007; 6: 257-66.
92. Arnold AC, Shaltout HA, Gallagher PE, et al. Protein phosphatase 1B activity in the solitary tract nucleus is necessary for normal baroreflex function. Hypertension 2009; 54: e100.
93. Gallagher PE, Ferrario CM, Tallant EA. MAP Kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 2008; 295: C1169-74.
94. Calka J, Block CH. Angiotensin-(1-7) and nitric oxide synthase in the hypothalamo-neuropophysial system. Brain Res Bull 1993; 30: 677-85.
95. Albrecht.D. Angiotensin-(1-7)-induced plasticity changes in the lateral amygdala are mediated by COX-2 and NO. Learn Mem 2007; 14: 177-84.
96. Zhang Y, Lu J, Shi J, et al. Central administration of angiotensin-(1-7) stimulates nitric oxide release and upregulates the endothelial nitric oxide synthase expression following focal cerebral ischemia/reperfusion in rats. Neuropeptides 2008; 42: 593-600.
97. Wright JW, Harding. The brain angiotensin system and extracellular matrix molecules in neuralplasticity, learning, and memory. Prog Neurobiol 2004; 72: 263-93.
98. Robbins ME, Diz DI. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 2006; 64: 6-12.
99. Kehoe AD, Nikiforov AM, Alexanin SS, et al. Angiotensinconverting enzyme genotype and encephalopathy in Chernobyl cleanup workers. Eur J Neurol 2009; 16: 95-100.
100. Kim JH, Brown SL, Kolozsvary A, et al. Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat Res 2004; 161: 137-42.
101. Jackson EK, Garrison JC. In: Hardman JG, Limbird LE Eds, Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, McGraw-Hill, 2001; 744.
102. Ryu S, Kolozsvary A, Jenrow KA, et al. Mitigation of radiationinduced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time. J Neurooncol 2007; 82: 119-24.
103. Brown WR, Blair RM, Moody DM, et al. Capillary loss precedes cognitive impairment induced by fractionated whole-brain irradiation. J Neurol Sci 2007; 257: 67-71.
104. 1 receptor antagonist, L-158,809, prevents or ameliorates fractionated wholebrain irradiation-induced cognitive impairment. Int J Radiat Oncol Biol Phys 2009; 73: 499-505.
105. Kasper SO, Basso N, Kurnjek ML, et al. Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. Am J Nephrol 2005; 25: 335-41.
106. 1 receptor antagonist L-158,809 on microglia and neurogenesis after fractionated whole-brain irradiation. Radiat Res (in press).
107. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881-900.
108. Blume A, Herdegen T, Unger T. Angiotensin peptides and inducible transcription factors. J Mol Med 1999; 77: 339-57.
109. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: 194-205.
110. Shimizu H, Miyoshi M, Matsumoto K, et al. The effect of central injection of angiotensin-converting enzyme inhibitor and the angiotensin type 1 receptor antagonist on the induction by lipopolysaccharide of fever and brain interleukin-1eeresponse in rats. J Pharmacol Exp Ther 2004; 308: 865-73.
111. Benicky J, Sánchez-Lemus E, Pavel J, et al. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Molec Neurobiol 2009; 29: 781-92.
112. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302: 1760-5.
113. Hanna IR, Taniyama Y, Szöcs K, et al. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 2002; 4: 899-914.
114. •-production by a non-phagocytic NADPH oxidase causes oxidant injury. J Biol Chem 2001; 276: 29251-6.
115. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003; 15: 247-54.
116. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313.
117. Infanger DW, Sharma RV, Davisson RL. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal 2006; 8: 1583-96.
118. Collins-Underwood JR, Zhao W, Sharpe JG, et al. NADPH oxidase mediates radiation-induced oxidative stress in rat brain microvascular endothelial cells. Free Radic Biol Med 2008; 45: 929-38.
119. Varagic J, Trask AJ, Jessup JA, et al. New angiotensins. J Mol Med 2008; 86: 663-71.
120. Chappell MC, Modrall JG, Diz DI, et al. Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol 2004; 143: 77-89.
121. Iyer SN, Chappell MC, Averill DB, et al. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with linopril and losartan. Hypertension 1998; 31: 699-705.
122. 1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 2009; 32: 533-6.
123. Al-Maghrebi M, Benter IF, Diz D. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacol Res 2009; 59: 263-8.
124. Benter IF, Yousif MHM, Dhaunsi GS, et al. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol 2008; 28: 25-33.
125. Ribeiro AB. Angiotensin II antagonists-therapeutic benefits spanning the cardiovascular disease cintinuum from hypertension to heart failure and diabetic nephropathy. Curr Med Res Opin 2006; 22: 1-16.
126. Molteni A, Ward WF, Ts'ao C, et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des 2003; 9: 751-61.